Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that entered the public markets through a business combination with Health Sciences Acquisitions Corporation, a healthcare-focused special purpose acquisition company whose IPO priced in 2018. Operating in the biopharmaceutical sector, Immunovant is focused on developing novel treatments for IgG-mediated autoimmune diseases, with its lead program batoclimab, an anti-FcRn monoclonal antibody, advancing across multiple indications. The company filed an 8-K with the Securities and Exchange Commission on September 15, 2021, under accession number 0001764013-21-000098, reflecting ongoing reporting obligations as an active post-merger public company. Sign up for SpacDesk to access the full filing history, sponsor details, and real-time data on Immunovant and thousands of other de-SPAC companies.